ROCKVILLE, Md., April 4, 2007 -- CytImmune, a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies has been selected to present a poster abstract at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago Illinois, June 1-5. The poster session will take place from 8:00 am to 12 noon on June 3. Dr. Lawrence Tamarkin, CEO of CytImmune will present the poster abstract entitled "Preliminary Results of a Phase I clinical trial of CYT-6091: A pegylated colloidal gold TNF nanomedicine.
"Acceptance to ASCO provides CytImmune the opportunity to present its research to the leading body of international oncology experts," said Dr. Lawrence Tamarkin, CEO of CytImmune Sciences. "For an emerging company, it's a chance interact with those in the field, advance science and demonstrate our role in the fight against cancer."
CYT-6091 (Aurimune), CytImmune's lead drug compound, is recombinant human tumor necrosis factor alpha (TNF) bound to the surface of 27 nanometer pegylated colloidal gold nanoparticles. While TNF's tumor killing properties are well documented, its clinical use has been severely limited due to unacceptable toxicities. To harness the potential of this anti-cancer agent, CytImmune's approach simultaneously binds PEG-Thiol and TNF to the surface of colloidal gold nanoparticles, whose design is to: (1) make them invisible to immune detection, thereby avoiding uptake by the liver and spleen and (2) target delivery of TNF directly to tumor sites. At 27 nanometers in size, CYT-6091 is able to exit the blood stream through leaky blood vessels and sequester in and around tumor sites with TNF binding to available receptors in this area. Preclinical studies indicate that CYT-6091 is then able to actively and passively target tumors, potentially delivering more drug to the site of disease with reduced side effects. The mechanism of targeting solid tumor